Research and Development
The Molecular Biology Institute of Paraná (IBMP) has been an innovator since its foundation and has made important contributions to Healthcare through the development of technologies such as the amplification module of the HIV/HCV/HBV NAT Kit besides other molecular tests for detecting different pathogens, already being manufactured in the production facility.
IBMP also invests its scientific and technological capacity in the development of new products, which seek to supply the needs in Healthcare of the Brazilian population and to nationalize production of molecular biology reagents used in the country. Working at the forefront of biotechnology, the researchers in the Institute develop molecular tests and biopharmaceuticals soon to be available both on the Brazilian market and on a global scale.
Find out more about our current projects:
Sepsis is a systemic inflammatory response syndrome induced by an infectious process predominantly caused by bacteria and fungi that invade the blood stream – it is the leading cause of death in ICUs worldwide, being an expensive burden for the health system and the society. IBMP is involved in the development of a platform for molecular diagnosis of the etiological agents that cause sepsis, encompassing a range of different markers present in most of the pathogens responsible for the infection. The objective of this product is to provide rapid identification of these agents to effectively guide treatment, allow the use of the most appropriate antibiotics to each situation, and to reduce mortality rates, length and costs of hospital stay.
Multiplex diagnosis for tropical diseases
Conceived for use during the Rio 2016 Olympics and Paralympics, the project focuses on the development of a fast diagnostic method for identifying the various diseases which are not diagnosed by conventional methods. The molecular kit – which uses the Polymerase Chain Reaction (PCR) – contains panels of primers which can be used in multiplex for sequencing and identifying bacteria, eukaryotic and viral pathogens in clinical samples, in order to prevent their dissemination.
Pregnancy care Project
In order to meet a demand of the Ministry of Health, IBMP has developed a diagnostic kit for detecting infectious agents during pregnancy. The initiative involves the development of a device for detecting and monitoring relevant diseases in pregnant women during prenatal follow-up. This is a multi-test platform able to detect a number of different diseases on a single blood sample, including AIDS, hepatitis B and C, rubella, syphilis, Chagas disease and toxoplasmosis. This test will be available in two versions: a device for rapid diagnosis at the point-of-care and an automated platform for health centers with the infrastructure for concomitantly analyzing a large amount of samples.
Personalized Medicine for Diagnosis and Treatment of Cancer
The genetic mapping of cancerous tumors is strategic for the individualized diagnosis of patients and to determine the best treatment as soon as possible. Using blood and tumor samples donated by the José Alencar Gomes da Silva National Cancer Institute (INCA), the Erasto Gaertner Hospital and the A.C. Camargo Cancer Center, IBMP is conducting studies to identify the molecular characteristics of different types of cancer, with an emphasis on genes which can be targets of novel therapies.
Multi-tests for serological screening
Funded by the Brazilian Economic and Social Development Bank (BNDES) and coordinated by Bio-Manguinhos, (Immunobiological Technology Institute of Fiocruz), the project seeks to develop a multi-test diagnostics kit for detection of the immunological response to infections by HIV-1, HIV-2, HTLV-1,HTLV-2, HBV, HCV, Treponema pallidum (the bacteria that causes syphilis) and Trypanosoma cruzi (parasite that causes Chagas disease), using a platform of liquid microarrays. The product is designed to analyse up to 92 blood samples in about two hours. IBMP is co-responsible for the stages of standardization, customization and initial validation of the kit.
Kit for detecting Whooping cough
A reemerging disease worldwide, whooping cough has gained renewed public health attention. Currently, the tests available for detecting the DNA of Bordetella pertussis, the bacteria responsible for causing the disease, are imported and rely on the cold chain for transport and storage. IBMP has developed a molecular-based test for detecting B. pertussis – using reagents produced by the Institute – that is optimized for being stored above freezing temperatures, eliminating the need for cold chain transport and storage.
Result of a partnership between IBMP and Brazilian and European research institutions – based in countries such as Germany, France, Portugal and Finland – the project goal is to develop a technology platform for diagnosing tropical diseases at points-of-care. Chagas disease was selected as the model for developing this diagnosis platform.
Recombinant Vaccine for Brucellosis
A globally spread zoonosis, brucellosis has an economic and social burden related to the risks posed to human health and the impact it causes on the productivity of herds. The disease is estimated to reduce milk and beef production by 25% and cattle fertility by 15%. In response to this situation, IBMP is developing a recombinant vaccine for brucellosis to express a differential marker distinguishing vaccination antibodies from those of the infection, and also devising a diagnostic test that discriminates antibodies produced against a differential marker.
Recombinant Fibrin Glue
Fibrin glue is a biological sealant that reduces hemorrhaging during cardiovascular, liver and orthopedic surgeries as well as neurosurgery. It has no contraindications or rejection risk. Although not a substitute for stitches, it acts as a complement, sealing the wound and speeding up the scarring process. The project is in response to a requirement of the Ministry of Health to meet the needs of the national market, with the product expected to be available by 2020.
Assessment of the Epidermal Growth Factor (EGF)
In recent years, treatment with EGF receptor inhibitors has proven effective in patients with lung cancer. Based on a need of the Ministry of Health to provide a high sensitivity national kit for quantifying this receptor, IBMP is working on a research project to assess EGF levels in patients with lung adenocarcinoma registered at institutions of the National Network of Clinical Research in Cancer.